[go: up one dir, main page]

MX2016010229A - Conjugados del factor vii. - Google Patents

Conjugados del factor vii.

Info

Publication number
MX2016010229A
MX2016010229A MX2016010229A MX2016010229A MX2016010229A MX 2016010229 A MX2016010229 A MX 2016010229A MX 2016010229 A MX2016010229 A MX 2016010229A MX 2016010229 A MX2016010229 A MX 2016010229A MX 2016010229 A MX2016010229 A MX 2016010229A
Authority
MX
Mexico
Prior art keywords
factor vii
vii conjugates
conjugates
conjugation
prevention
Prior art date
Application number
MX2016010229A
Other languages
English (en)
Inventor
Behrens Carsten
Deangelis Paul
Michael Haller Friedrich
Original Assignee
Novo Nordisk Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk Healthcare Ag filed Critical Novo Nordisk Healthcare Ag
Publication of MX2016010229A publication Critical patent/MX2016010229A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona con la conjugación de polipéptidos del Factor VII con polímeros de heparosan. Los conjugados resultantes pueden usarse para liberar el Factor VII, por ejemplo, en el tratamiento o prevención de trastorno hemorrágico.
MX2016010229A 2014-02-12 2015-02-12 Conjugados del factor vii. MX2016010229A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14154875 2014-02-12
PCT/EP2015/053028 WO2015121385A1 (en) 2014-02-12 2015-02-12 Factor vii conjugates

Publications (1)

Publication Number Publication Date
MX2016010229A true MX2016010229A (es) 2016-11-15

Family

ID=50071543

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016010229A MX2016010229A (es) 2014-02-12 2015-02-12 Conjugados del factor vii.

Country Status (13)

Country Link
US (1) US20150225711A1 (es)
EP (1) EP3104894A1 (es)
JP (1) JP2017507133A (es)
KR (1) KR20160122158A (es)
CN (1) CN106358440A (es)
AR (1) AR099328A1 (es)
AU (1) AU2015216988A1 (es)
BR (1) BR112016017644A2 (es)
CA (1) CA2939577A1 (es)
IL (1) IL246349A0 (es)
MX (1) MX2016010229A (es)
RU (1) RU2016134328A (es)
WO (1) WO2015121385A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150259665A1 (en) * 2012-10-15 2015-09-17 Novo Nordisk Health Care Ag Factor vii conjugates
KR20160065925A (ko) 2013-10-15 2016-06-09 노보 노르디스크 헬스 케어 악티엔게젤샤프트 응고 인자 vii 폴리펩티드
AR099340A1 (es) * 2014-02-12 2016-07-13 Novo Nordisk As Conjugados del factor de coagulación ix
CN107118277B (zh) * 2017-07-12 2020-12-04 苏州博赛生物医药有限公司 一种单克隆抗体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0614839A2 (pt) * 2005-08-19 2009-05-19 Neose Technologies Inc fator vii e fator viia glicopeguilados
US20090055942A1 (en) * 2005-09-14 2009-02-26 Novo Nordisk Healthcare A/G Human Coagulation Factor VII Polypeptides
US9687559B2 (en) * 2008-03-19 2017-06-27 The Board Of Regents Of The University Of Oklahoma Heparosan polymers and methods of making and using same for the enhancement of therapeutics
TWI465247B (zh) * 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
WO2011101242A1 (en) * 2010-02-16 2011-08-25 Novo Nordisk A/S Factor viii molecules with reduced vwf binding
US20150259665A1 (en) * 2012-10-15 2015-09-17 Novo Nordisk Health Care Ag Factor vii conjugates
CN105008530A (zh) * 2013-03-12 2015-10-28 诺和诺德股份有限公司 凝血酶敏感性凝固因子x分子

Also Published As

Publication number Publication date
CN106358440A (zh) 2017-01-25
EP3104894A1 (en) 2016-12-21
BR112016017644A2 (pt) 2017-10-17
JP2017507133A (ja) 2017-03-16
AU2015216988A1 (en) 2016-07-07
AR099328A1 (es) 2016-07-13
CA2939577A1 (en) 2015-08-20
IL246349A0 (en) 2016-08-31
KR20160122158A (ko) 2016-10-21
US20150225711A1 (en) 2015-08-13
WO2015121385A1 (en) 2015-08-20
RU2016134328A (ru) 2018-03-15

Similar Documents

Publication Publication Date Title
ZA202502076B (en) Chimeric neurotoxins
ZA201803366B (en) Antibody molecules to april and uses thereof
MX2020014121A (es) Agonistas parciales del receptor de insulina.
PH12016501763A1 (en) Multispecific antibodies
PH12016502142B1 (en) Anti-ptk7 antibody-drug conjugates
MD4801B1 (ro) Antagonişti ai activin-ActRII şi utilizarea lor pentru tratamentul sindroamelor mielodisplazice
MX2022001043A (es) Moleculas de anticuerpo que se unen a lag-3 y usos de las mismas.
NZ733055A (en) Anti-c10orf54 antibodies and uses thereof
NZ725568A (en) Modified j-chain
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MA40460A (fr) Ciblage lysosomial et utilisation correspondante
MX379622B (es) Compuestos espirociclicos
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
MY190747A (en) Method for producing silazane-siloxane copolymers and the use of such copolymers
ZA201803476B (en) Anti-cd22 antibody-maytansine conjugates and methods of use thereof
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.
MY181685A (en) Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer
WO2014147503A3 (en) Anti-bag3 antibodies for therapeutic use
MX2016010229A (es) Conjugados del factor vii.
EP4541423A3 (en) Dosing regimen of avelumab for the treatment of cancer
MX2016001691A (es) Moleculas de union al receptor bag3 para uso como un medicamento.
TW201613650A (en) FVIII conjugates
MX356906B (es) Un concentrado de suspension y metodos asociados de uso.
PH12014000104A1 (en) Therapeutic methods and compositions for treating diabetes
UA99992U (ru) 2-оксо-4-фенил-5-циано-1,2,3,4-тетрагидропиридин-6-тиолат n-метилморфолиния